by Damon Race | Aug 29, 2023 | In the News
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Damon Race, CEO of GeneVentiv Therapeutics. The North Carolina-based startup hopes to develop a universal gene therapy that will benefit patients with hemophilia A or B with or without...
by Damon Race | Aug 29, 2023 | Press
August 29, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has added Robert Baffi and Deborah Wild as Advisors as the Company prepares...
by Damon Race | Jun 8, 2022 | In the News
Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
by Damon Race | Feb 8, 2022 | In the News
by Shellie Edge, Innovate Carolina — February 8, 2022 . Editor’s note: Startup Spotlight is a regular weekly feature in WRAL TechWire. This week’s feature comes from UNC-Chapel Hill’s Innovate Carolina. +++ CHAPEL HILL – For most people, a small cut on the hand or...
by Damon Race | Nov 2, 2021 | Press
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
Recent Comments